Julia Thornton Snider, PhD

Treatment delays limit the social value generated by chimeric antigen receptor (CAR) T-cell therapy for the treatment of pediatric acute lymphoblastic leukemia and diffuse large B-cell lymphoma.

This study compares the well-being of long-term cancer survivors with that of US residents of similar age and demographic characteristics, patients recently diagnosed with cancer, and individuals with chronic illness.

Option value is the benefit a therapy provides patients by enabling them to survive to the next innovation.

Vaccination of children born in the United States in 2009 will save 1.2 million quality-adjusted life-years, generating $184 billion in social value net of vaccination costs.

An analysis of claims from over 90,000 patients with type 2 diabetes (T2D) demonstrates that increased medication cost sharing is associated with higher rates of hospitalization and increased plan costs.

Instrumental variables regression analysis indicated that inpatient oral nutritional supplement use decreased length of stay, episode cost, and 30-day readmission probability.